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CARDIOVASCULAR RISK AND BLOOD PRESSURE
REDUCTION: AN OVERVIEW OF THE OUTCOME
TRIALS
J. A. Staessen, J. G. Wang, L. Thijs. 1Hypertension Unit, University of
Leuven, Leuven, Belgium
We performed a quantitative overview of the literature to investigate
whether properties of antihypertensive drugs may play a role in cardio-
vascular protection over and beyond blood pressure (BP) lowering. We
extracted summary statistics from published articles and computed
pooled odds ratios (ORs) for experimental vs reference treatment from
stratified 2 x 2 contingency tables after application of Zelen’s test of
heterogeneity. Subsequently, we correlated ORs with BP differences
across individual trials, using meta-regression. Among 5 trials in hyper-
tension which compared cardiovascular risk on diuretics or b-blockers
with that on calcium-channel blockers (CCBs) or angiotensin-converting
enzyme (ACE) inhibitors, all drug classes offered similar cardiovascular
protection. However, on CCBs there was more reduction in the risk of
stroke (15.1%, CI 2.8–25.9%, p50.02) and less reduction in the risk of
myocardial infarction (20.1%, CI 3.90–38.9%, p50.01). Meta-regression
across 21 trials showed that for cardiovascular mortality the relationship
between the ORs and BP differences was linear, whereas for other
outcomes there was no further decrease in risk once the systolic/diastolic
differences had reached ~15/5 mm Hg. In recent trials of doxazosin vs
chlorthalidone in hypertensive patients and of ramipril vs placebo in
high-risk patients, outcome was better on the diuretic and the ACE
inhibitor, respectively. However, there were also 2-3/1 mm Hg BP
differences between the groups. For systolic BP in the 2 trials, all ORs
conformed with the regression lines. For diastolic BP, there was also no
separation between predicted (0.99, CI 0.88–1.10) and observed ORs,
except for the risk of all cardiovascular events on doxazosin (1.24, CI
1.15–1.33) or ramipril (0.76 CI 0.67–0.85). In conclusion, in the recent
trials BP largely accounts for outcome. Older and newer antihypertensive
drugs provide similar overall cardiovascular benefit, but CCBs may offer
more protection against stroke than myocardial infarction. The hypoth-
esis that ACE inhibitors or a-blockers might influence outcome over and
beyond their BP lowering effects remains to be proven.
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ANGIOTENSIN II ANTAGONISTS DEMONSTRATE
GREATER LONG-TERM PERSISTENCE VERSUS
OTHER ANTIHYPERTENSIVE MEDICATIONS
Stephen J. Boccuzzi, Jim Fox, James B. Roehm, William C. Gerth,
Paul R. Conlin. 1Endocinology-Hypertension Division, Brighan and
Womens Hospital, Boston, MA, United States, 2The Institute for
Effectiveness Research L.L.C., A Merck Company, Bridgewater, NJ,
United States, 3Outcomes Research, Merck & Co., Inc., Whitehouse
Station, NJ, United States
In a previous analysis Bloom (Clinical Therapeutics 1998) demonstrated
that losartan, an angiotensin II antagonist (AIIA), had greater 1-year
persistence compared to other antihypertensive medications possibly due
to the improved tolerability of this new class of agents. To investigate
longer-term rates of persistence, the available members of the original
Bloom cohort (N521,723) were identified from the Merck-Medco Man-
aged Care administrative pharmacy claims database and re-analyzed over
a 4 year follow-up period (7/01/95-6/30/00).
A cohort of 15,175 patients was continuously benefit eligible over the
4-year follow-up study period, with 451 patients receiving AIIA therapy,
4,428 angiotensin converting enzyme inhibitor (ACE), 3,892 calcium
channel blocker (CCB), 3,808 beta-blocker (BB) and 2,596 thiazide
diuretic (D) therapy. The cohort had a mean age of 56 years; 28% .65
years of age and 55% were female. Greater persistence by the AIIA class
at 12 months (mo) maintained statistical significance (two-sided chi-
square, a 5 0.05) verses all other classes of antihypertensive agents at 24
mo (p , 0.007) and 36 mo (p ,0.01). At 48 mo this improved AIIA
persistence was statistically significant versus CCB, BB and D (p , 0.03)
with a statistical trend for ACE (p 5 0.095). Fewer patients in the BB and
D class were persistent at 48 mo with approximately half of the BB and
D patients not receiving any hypertensive therapy by the end of the
follow-up period. Twenty percent of patients in each therapeutic group
switched to another antihypertensive class by year 4, except for D in
which 33% of patients switched.
This analysis demonstrates that the superior persistency of the AIIA
class at 12-months is maintained for at least 36 and possibly 48 months
despite a general decrease in persistency for all agents over time. At the
time this analysis was initiated losartan was the only commercially
available AIIA and these results may not be generalizable to other AIIA.
In conclusion, these findings may have relevance regarding initial agent
selection for pharmacologic management of hypertension.
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DOUBLE-BLIND, PLACEBO-CONTROLLED
CROSSOVER ROTATION OF THE FIVE PRINCIPAL
CLASSES OF ANTIHYPERTENSIVE DRUGS
Alison J. Deary, Anne L. Schumann, Helen Murfet, Stephen F.
Haydock, Morris J. Brown. 1Clinical Pharmacology Unit, University
of Cambridge, Cambridge, United Kingdom
Outcome studies in hypertension show that achieved BP is more impor-
tant than choice of initial treatment. Meta-analyses report risk ratios of
1.0 for either calcium blockers (CCB) or ACE inhibitors (ACEi) vs.
bblockers (bB) or diuretics (D), but 0.8 for more vs. less intensive
reduction in BP by any regimen. We previously reported an open-label
rotation through four of the main classes, which demonstrated an ap-
proximate doubling of patients controlled on monotherapy after rotation
vs. their first drug. We have now completed a more formal study, whose
objectives were to demonstrate whether there is true inter-individual
response to the classes, and to determine any predictors of resistance to
monotherapy.
We studied 25 men and 9 women, aged 28-55 (median 47), with
previously untreated hypertension (BP 160612/10165 mmHg after 3
readings over 3 months). They received in random order amlodipine 5
mg (CCB), lisinopril 10 mg (ACEi), bisoprolol 5 mg (bB), bendroflua-
zide 2.5 mg (D), doxazosin (4 mg) (a-blocker) and placebo once daily for
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